María Fernanda
López Fernández
Hospital Vall d'Hebron
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Vall d'Hebron (19)
2023
-
von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS
Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 4, pp. 787-799
2022
-
Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study
Journal of Thrombosis and Haemostasis, Vol. 20, Núm. 5, pp. 1106-1114
2021
-
A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients
Blood Cells, Molecules, and Diseases, Vol. 86
-
Author Correction: Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia (Scientific Reports, (2019), 9, 1, (16680), 10.1038/s41598-019-53209-y)
Scientific Reports
-
Expert opinion paper on the treatment of hemophilia B with albutrepenonacog alfa
Expert Opinion on Biological Therapy, Vol. 21, Núm. 9, pp. 1165-1171
-
Type 2N VWD: Conclusions from the Spanish PCM-EVW-ES project
Haemophilia, Vol. 27, Núm. 6, pp. 1007-1021
2020
-
Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study
Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 9, pp. 2145-2154
2019
-
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia
Scientific Reports, Vol. 9, Núm. 1
-
Management of adult patients with primary immune thrombocytopenia (itp) in clinical practice: A consensus approach of the Spanish itp expert group
Advances in Hematology, Vol. 2019
2018
2017
-
Molecular and clinical profile of von willebrand disease in Spain (PCM-EVW-ES): Comprehensive genetic analysis by next-generation sequencing of 480 patients
Haematologica, Vol. 102, Núm. 12, pp. 2005-2014
2016
-
Immune tolerance induction in patients with haemophilia a and inhibitors: Effectiveness and cost analysis in an European Cohort (The ITER Study)
Haemophilia, Vol. 22, Núm. 1, pp. 96-102
-
Molecular and clinical profile of von willebrand disease in spain (PCM-EVW-ES): Proposal for a new diagnostic paradigm
Thrombosis and Haemostasis, Vol. 115, Núm. 1, pp. 40-50
-
Practical aspects of DDAVP use in patients with von Willebrand Disease undergoing invasive procedures: A European survey
Haemophilia, Vol. 22, Núm. 1, pp. 110-120
-
Practical aspects of factor concentrate use in patients with von Willebrand disease undergoing invasive procedures: a European survey
Haemophilia, Vol. 22, Núm. 5, pp. 739-751
-
Spanish consensus guidelines on prophylaxis with bypassing agents for surgery in patients with haemophilia and inhibitors
European Journal of Haematology, Vol. 96, Núm. 5, pp. 461-474
2012
-
Continuous infusion in haemophilia: Current practice in Europe
Haemophilia, Vol. 18, Núm. 5, pp. 753-759
2010
-
Non-genetic risk factors and the development of inhibitors in haemophilia: A comprehensive review and consensus report
Haemophilia, Vol. 16, Núm. 5, pp. 747-766
1996
-
Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects
Annals of Hematology, Vol. 72, Núm. 5, pp. 321-326